Genzyme (GENZ-$49.63) has already spent more than $1 billion in the last two years to build new and bigger bioreactors — notably in the U.S., Ireland, and Belgium. Eventual plans call for total perfusion bioreactor capacity to climb from 20,000 Liters to 32,000 Liters by 2012. The global brewer of enzyme replacement therapies for rare genetic diseases disclosed this week that the FDA was delaying final approval of the company’s application to market Lumizyme (alglucosidase alfa) for the treatment of Pompe disease.
Can Genzyme finally redress its quality control problems at Allston Landing and keep unwanted particles out of its enzyme stews? Find out at BNET Pharma….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.